Hyperglycemia Potentiates the Slowing of Gastric Emptying Induced by Exogenous GLP-1

• DOI: 10.2337/dc14-3091
• Publication Date: 2015-03-18T02:33:18Z
• Authors: Mark P. Plummer; Karen L. Jones; Caroline E. Cousins; Laurence G. Trahair; Juris J. Meier; Marianne J. Chapman; Michael Horowitz; Adam M. Deane
• Keywords: Blood Glucose; Male; Infusions; 610; 03 medical and health sciences; gastric emptying; 0302 clinical medicine; Double-Blind Method; Gastrointestinal Agents; Glucagon-Like Peptide 1; Diabetes Mellitus; blood glucose; Humans; Hypoglycemic Agents; Insulin; Infusions, Intravenous; Aged; Analysis of Variance; Middle Aged; Healthy Volunteers; 3. Good health; Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Hyperglycemia; Female; hyperglycemia; Intravenous; Type 2

OBJECTIVE Acute hyperglycemia markedly slows gastric emptying. Exogenous GLP-1 also emptying, leading to diminished glycemic excursions. The primary objective was determine whether potentiates the slowing of emptying induced by administration. RESEARCH DESIGN AND METHODS Ten healthy participants were studied on 4 separate days. Blood glucose clamped at using an intravenous infusion 25% dextrose (∼12 mmol/L; hyper) 2 days, or maintained euglycemia (∼6 eu) between t = −15 and 240 min. During hyperglycemic euglycemic received (1.2 pmol/kg/min) placebo in a randomized double-blind fashion. At 0 min, subjects ingested 100 g beef mince labeled with 20 MBq technetium-99m–sulfur colloid 3 3-O-methyl-glucose (3-OMG), marker absorption. Gastric measured scintigraphically from min serum 3-OMG taken regular intervals 15 areas under curve for analyzed one-way repeated-measures ANOVA Bonferroni-Holm adjusted post hoc tests. RESULTS Hyperglycemia slowed (eu/placebo vs. hyper/placebo; P < 0.001) as did eu/GLP-1; 0.001). There additive effect hyperglycemia, such that slower compared administration during (eu/GLP-1 hyper/GLP-1; 0.01). CONCLUSIONS exogenous profoundly excess euglycemia. Studies are required effects subcutaneously administered commercially available agonists patients type diabetes.